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Abstract 
Background: The effects of sodium‑glucose cotransporter 2 inhibitor (SGLT2i) on cardiac function are not fully 
understood. We investigated the changes in cardiac function in diabetic patients according to the presence and types 
of heart failure (HF).
Methods: We retrospectively identified 202 diabetic patients who underwent echocardiography before, and 6 to 
24 months after the initiation of SGLT2i. After propensity score matching with diabetic patients without SGLT2i, the 
study population (n = 304) were categorized into group 1 (without HF nor SGLT2i; n = 76), group 2 (without HF and 
received SGLT2i; n = 78), group 3 (with HF but without SGLT2i; n = 76), and group 4 (with HF and received SGLT2i; 
n = 74). Changes in echocardiographic parameters were compared between these 4 groups, and between HF 
patients with reduced versus preserved ejection fraction (EF).
Results: After a median 13 months of follow‑up, HF patients with SGLT2i showed a significant decrease in left ventric‑
ular end‑diastolic dimension (LV‑EDD; from 57.4 mm [50.0–64.9] to 53.0 mm [48.0–60.0]; p < 0.001) and improvement 
in LV‑EF (from 36.1% [25.6–47.5] to 45.0% [34.8–56.3]; p < 0.001). LV mass index and diastolic parameters also showed 
improvements in HF patients with SGLT2i. The SGLT2i‑induced improvements in cardiac function were more promi‑
nent in HF patients than those without HF, and in HFrEF patients than HFpEF patients.
Conclusions: Use of SGLT2i improved cardiac function in diabetic patients, regardless of the presence of HF. The 
improvements were more prominent in HF patients, especially in those with HFrEF. These improvements in cardiac 
function would contribute to the clinical benefit of SGLT2i.
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Background
Sodium glucose co-transporter 2 (SGLT2) is the major 
cotransporter involved in glucose reabsorption in the 
kidney, and the inhibition of SGLT2 has been estab-
lished as a novel therapeutic measure for diabetic con-
trol. In particular, the SGLT2 inhibitors (SGLT2i) have 
demonstrated robust benefits in terms of the prevention 
of heart failure (HF) and the reduction in cardiovascular 
mortality, which was the first evidence for prevention 
of major cardiovascular events by anti-diabetic medi-
cations. Several large-scale trials showed concordant 
results of SGLT2i for HF prevention [1–3].
Adding to the glucose lowering effect of SGLT2i, 
several glucose-independent mechanisms have been 
suggested for HF prevention: preload and afterload 
reduction by natriuresis and osmotic diuresis, improve-
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myocardial necrosis and fibrosis, and alteration in adi-
pokines [4]. These hypotheses were further supported 
by the recently published trial of dapagliflozin, the Dapa-
gliflozin and Prevention of Adverse-outcomes in Heart 
Failure (DAPA-HF) trial, which extended the benefits of 
SGLT2i to those with HF with reduced ejection fraction 
(HFrEF) even in the absence of diabetes.
Despite the well-established clinical benefits of SGLT2i, 
only limited studies on the changes in cardiac function by 
SGLT2i have been made so far. Furthermore, it is unclear 
whether the cardiovascular benefits of SGLT2i would be 
similar between the diabetic patients with versus without 
HF, and between those with HFrEF versus HFpEF. We 
aimed to compare the SGLT2i-induced changes in car-
diac function and geometry assessed by echocardiogra-
phy in type 2 diabetic patients according to the presence 
and types of HF, using a retrospective cohort.
Methods
Patients
This retrospective (cohort) study was carried out accord-
ing to the principles of the Declaration of Helsinki and 
was approved by the Clinical Research Institute of Seoul 
National University Bundang Hospital (approved on 
March 11 2019; IRB No. B-1903-531-105).
From October 2014 to April 2019, we retrospectively 
identified 2819 patients with type 2 diabetes who vis-
ited Seoul National University Bundang Hospital and 
were prescribed with SGLT2i (1679 patients prescribed 
with dapagliflozin; 1131 with empagliflozin; and 9 with 
ipragliflozin) (Fig.  1). Comorbidities of patients were 
determined from the electronic medical record. Patients 
without echocardiography or with only 1 echocardiogra-
phy were excluded. Among the patients with 2 or more 
echocardiograms, those with the interval of two echocar-
diograms < 6  months or > 24  months were excluded. 
Patients for whom echocardiograms were performed 
during hospitalization for acute HF were also excluded. 
Using these exclusion criteria, 8039 diabetic patients 
without SGLT2i prescription were identified.
For the patients with SGLT2i prescription, those 
with all echocardiograms performed before, but not 
after, the initial SGLT2i prescription were excluded. 
Patients with all echocardiograms performed after, 
but not before, the initial SGLT2i prescriptions 
were also excluded. In addition, patients with no 
Fig. 1 Flow chart of study population. SGLT2i sodium‑glucose cotransporter 2 inhibitor, HF heart failure
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echocardiography performed 6–24  months after the 
initial SGLT2i prescription were excluded. After exclu-
sion, 202 diabetic patients for whom SGLT2i were pre-
scribed, and for whom the baseline echocardiography 
was performed before the initial SGLT2i prescription 
and the follow-up echocardiography was performed at 
6–24 months after the initial SGLT2i prescription were 
identified.
Using the propensity score matching with 1:1 ratio 
for age, sex, hypertension, dyslipidemia, coronary 
artery disease, HF, chronic kidney disease, atrial fibril-
lation, and interval of echocardiogram, the 202 dia-
betic patients with SGLT2i prescription were matched 
to 8039 diabetic patients without SGLT2i (Additional 
file 1: Table S1). The definition of coronary artery dis-
ease was a presence of ≥ 50% diameter-stenosis on 
invasive coronary angiography or computed tomog-
raphy angiography, a presence of perfusion decrease 
on myocardial perfusion imaging, or a positive result 
on treadmill test. HF was defined as the presence of 
New York Heart Association functional class ≥ II and 
elevated N-terminal pro-B-type natriuretic peptide 
(NT-proBNP; > 125 pg/mL) or echocardiographic find-
ings suggestive of HF (left ventricular ejection frac-
tion [LV-EF] < 40%, diastolic dysfunction, or other 
relevant structural heart disease including LV hyper-
trophy and/or left atrial enlargement), according to the 
clinical guidelines [5, 6]. The chronic kidney disease 
was defined as the glomerular filtration rate < 60  mL/
min/1.73 m2.
The propensity score matching was successful, and 
a total of 152 diabetic patients on SGLT2i and a total 
of 152 diabetic patients without SGLT2i were identi-
fied (Fig. 1). We categorized the study population into 4 
groups divided according to the presence of HF and the 
prescription of SGLT2i: diabetic patients without HF 
and without SGLT2i (group 1; n = 76), diabetic patients 
without HF and with SGLT2i (group 2; n = 78), diabetic 
patients with HF but without SGLT2i (group 3; n = 76), 
and diabetic patients with HF and with SGLT2i (group 
4; n = 74).
Echocardiography and strain analysis
Results of the baseline and follow-up echocardiography 
were obtained from the database. Standard techniques 
were used to obtain M-mode, 2-dimensional, and Dop-
pler measurements in accordance with the guidelines 
[7]. The LV global longitudinal strain (LV-GLS) measure-
ments were performed by experienced echocardiography 
specialists in a blinded fashion using TomTec software 
(Image Arena 4.6, Munich, Germany), according to 
current guidelines [8]. We took the absolute value |x| of 
LV-GLS for simpler interpretation.
Study outcomes
The study outcomes were the changes in echocardio-
graphic parameters of LV geometry (LV end-diastolic 
dimension [LV-EDD], LV end-diastolic volume [LV-
EDV], and LV mass index [LV-MI]), systolic function 
(LV-EF and LV-GLS), and diastolic function (mitral E/e’ 
ratio, and the estimated pulmonary artery systolic pres-
sure [PASP]).
The changes in echocardiographic parameters were 
compared between the four subgroups divided accord-
ing to the presence of HF and the SGLT2i prescrip-
tion. In addition, as a sensitivity analysis, we compared 
the changes in echocardiographic parameters accord-
ing to the use of SGLT2i between patients with HF with 
reduced EF (LV-EF < 40% at baseline) and those with HF 
with preserved EF (HFpEF) (LV-EF ≥ 40% at baseline).
Statistical analysis
Categorical variables are presented as frequencies and 
percentages, and continuous variables as means ± stand-
ard deviations (SD) or medians with interquartile ranges 
(IQR). Group comparisons were performed with student 
t test or paired t-test for normally distributed data and 
the Wilcoxon matched pairs test when data were non-
normal. The χ2 test or the Fisher’s exact test was used 
for categorical variables. In order to assess the associa-
tion between the use of SGLT2i and the improvement 
LV-EF, we used logistic regression analysis for the +5% 
improvement in LV-EF and for the +10% improvement 
in LV-EF. Multivariable logistic regression analysis with 
stepwise backward elimination method was performed 
all variables of p-values < 0.20 by univariate analyses. All 
of the statistical analyses were performed using SPSS 21.0 
(SPSS Inc, Chicago, Ill) and a p-value < 0.05 was consid-
ered statistically significant.
Results
Baseline characteristics and candidate predictors
In total study population, the median age was 66  years 
(56–74), and 65% were male (Table  1). Prevalence of 
comorbidities were not different across the subgroups. 
Eighty-two percent of patients were on metformin, 60% 
were on sulfonylurea, and 69% were on DPP-4 inhibi-
tors. The levels of fasting serum glucose and HbA1c were 
not different across the subgroups. The median follow-
up interval of the total study population was 13 (8–20) 
months, and was not different between the subgroups.
The types and doses of SGLT2i were not differ-
ent between group 2 vs. 4 (Table  1 and Additional 
file  1: Table  S2). Eighty-three patients (27.3%) were on 
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Group 1 No 
HF, no SGLT2i 
(n = 76)
Group 2 No 





Group 3 HF 
(+), no SGLT2i 
(n = 76)
Group 4 HF 





Age (years) 66 (56–74) 66 (58–72) 65 (56–72) 0.470 67 (56–75) 67 (54–75) 0.950








76 (68–85) 75 (70–81) 78 (65–88) 0.876 78 (68–85) 76 (68–84) 0.800
Heart rate (per 
minute)
79 (68–91) 76 (66–87) 75 (68–83) 0.638 83 (68–99) 83 (71–97) 0.635
NYHA functional 
class III/IV
53 (17.4%) 0 (0.0%) 0 (0.0%) N/A 26 (34.2%) 27 (36.5%) 0.771
Hypertension 149 (49.9%) 37 (48.7%) 31 (39.7%) 0.264 43 (56.6%) 38 (51.4%) 0.631
Dyslipidemia 101 (33.2%) 25 (32.9%) 23 (29.5%) 0.648 27 (35.5%) 26 (35.1%) 0.960
Coronary artery 
disease
110 (36.2%) 26 (34.2%) 31 (39.7%) 0.477 27 (35.5%) 26 (35.1%) 0.828
Chronic kidney 
disease
36 (11.8%) 10 (13.2%) 8 (10.3%) 0.575 9 (11.8%) 9 (12.2%) 0.952
Atrial fibrillation 96 (31.6%) 13 (17.1%) 14 (17.9%) 0.891 36 (47.4%) 33 (44.6%) 0.858
Medications
 Use of SGLT2i
  Dapagliflozin 69 (22.7%) 0 (0.0%) 39 (50.0%) N/A 0 (0.0%) 29 (39.2%) N/A
  Empagliflozin 83 (27.3%) 0 (0.0%) 39 (50.0%) N/A 0 (0.0%) 45 (60.8%) N/A
Duration of SGLT2i 
use (months)
– – 10 (5–15) N/A – 10 (7–15) N/A
 Statin 254 (83.6%) 69 (90.8%) 68 (87.2%) 0.475 58 (76.3%) 59 (79.7%) 0.614
 Metformin 249 (81.9%) 59 (77.6%) 63 (80.8%) 0.631 61 (80.3%) 66 (89.2%) 0.174
 Sulfonylurea 184 (60.5%) 38 (50.0%) 50 (64.1%) 0.077 45 (59.2%) 51 (68.9%) 0.216
 DPP‑4 inhibitors 210 (69.1%) 47 (61.8%) 56 (71.8%) 0.189 55 (72.4%) 52 (70.3%) 0.776
 ACE inhibitors 107 (35.2%) 20 (26.3%) 26 (33.3%) 0.341 29 (38.2%) 32 (43.2%) 0.526
 ARB 161 (53.0%) 41 (53.9%) 38 (48.7%) 0.516 42 (55.3%) 40 (54.1%) 0.882
 Beta‑blockers 255 (83.9%) 58 (76.3%) 61 (78.2%) 0.780 67 (88.2%) 69 (93.2%) 0.284
 MRA 103 (33.9%) 9 (11.8%) 9 (11.5%) 0.953 40 (52.6%) 45 (60.8%) 0.312
 Diuretics 179 (58.9%) 23 (30.3%) 31 (39.7%) 0.218 59 (77.6%) 66 (89.2%) 0.079
Baseline laboratory tests
 Hemoglobin (g/dL) 13.8 (12.7–15.1) 13.7 (12.8–15.0) 14.1 (13.1–15.0) 0.368 13.7 (12.3–15.3) 13.6 (12.1–15.3) 0.624
 Serum creatinine 
(mg/dL)
0.9 (0.8–1.1) 0.9 (0.7–1.1) 0.9 (0.8–1.1) 0.839 1.0 (0.8–1.2) 1.0 (0.8–1.3) 0.806
 Total cholesterol 
(mg/dL)









 Fasting glucose 
(mg/dL)









 HbA1c (%) 7.1 (6.5–8.0) 7.3 (6.6–7.8) 7.5 (6.6–8.6) 0.095 6.8 (6.4–7.8) 6.9 (6.4–7.7) 0.905
 NT‑proBNP  
(pg/mL)
447.7 (106.9–






3386.1) (n = 70)
1819.6 (547.3–
5695.4) (n = 71)
0.637
Echocardiographic parameters
 LV‑EDV (mL) 92.0 (69.0–128.5) 76.0 (64.5–96.5) 79.5 (65.0–97.0) 0.430 111.9 (82.5–148.5) 128.5 (94.0–169.0) 0.098
 LV‑ESV (mL) 41.0 (28.9–80.7) 29.6 (23.5–42.8) 32.0 (25.0–42.0) 0.486 69.5 (33.0–112.0) 82.5 (41.0–125.0) 0.115
 LV‑EDD (mm) 50.9 (46.5–80.0) 48.0 (44.5–50.0) 49.0 (45.0–52.0) 0.174 56.1 (49.5–62.0) 57.4 (50.0–64.9) 0.203
 LV‑ESD (mm) 35.7 (30.0–47.0) 31.0 (28.4–35.5) 32.0 (28.0–36.0) 0.658 44.0 (32.5–51.0) 45.4 (37.0–54.0) 0.181
 LV‑EF (%) 52.0 (35.6–61.1) 60.4 (52.4–63.8) 59.4 (49.3–63.6) 0.628 38.8 (28.0–55.9) 36.1 (25.6–47.5) 0.094
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empagliflozin, and 69 (22.7%) on dapagliflozin. The 
duration of SGLT2i use was 10 (5–15) months in group 
2, and was 10 (7–15) months in group 4. Use of angio-
tensin converting enzyme inhibitors (ACEi), angiotensin 
receptor blocker (ARB), beta-blockers, mineralocorticoid 
antagonists (MRA), and diuretics were more frequent 
in patients with HF (groups 3 and 4) compared to those 
without HF (groups 1 and 2), but were not different 
according to the use of SGLT2i (groups 1 vs. 2; groups 
3 vs. 4). Also, the types of cardioprotective medications 
(ACEi, ARB, beta-blockers, and MRA) and their changes 
during follow-up were not different according to the use 
of SGLT2i. Detailed information on the use of medica-
tions are summarized in Additional file 1: Table S2.
Comparison of echocardiographic parameters according 
to the presence of HF
At baseline, the patients with HF (groups 3 and 4) had 
worse echocardiographic parameters compared to those 
without HF (groups 1 and 2), but there was no difference 
according to the use of SGLT2i, both in those without 
HF (groups 1 vs. 2) and in those with HF (groups 3 vs. 4) 
(Table 1).
At follow-up, the LV geometry showed significant 
differences according to the use of SGLT2i and to the 
presence of HF (Fig.  2). In patients without HF, those 
with SGLT2i treatment showed a small but significant 
decrease in LV-EDD (from 49.0 [45.0–52.0] to 47.0 mm 
[44.0–51.0]; p = 0.036), but those without SGLT2i did not 
(p for interaction = 0.041) (Fig.  2a). In the HF patients, 
we observed a significant decrease in LV-EDD (from 57.4 
[50.0–64.9] to 53.0 mm [48.0–60.0]; p < 0.001), as well as 
LV-MI (from 126.3 [111.1–147.3] to 115.2  g/m2 [97.0–
137.8]; p = 0.026) in SGLT2i treated group, but not in 
the HF patients without SGLT2i treatment (p for interac-
tion = 0.004 for LV-EDD, < 0.001 for LV-MI) (Fig. 2a, b).
In patients without HF, the SGLT2i users showed a 
significant increase in LVEF in group 2 (from 59.4 [49.3–
63.6] to 61.6% [55.6–65.7]; p < 0.001) but not in the group 
1 (from 60.4 [52.4–63.8] to 60.2% [52.1–63.3]) (Fig.  2c). 
Similarly, the LV-GLS was improved in group 2 but not in 
group 1 (Fig. 2d). In the HF patients, those with SGLT2i 
treatment (group 4) showed a prominent improvement 
in LV-EF (from 36.1 [25.6–47.5] to 45.0% [34.8–56.3]; 
p < 0.001) as well as LV-GLS (from 10.3 [7.3–12.5] to 
11.4% [8.4–14.3]; p = 0.001). The HF patients without 
SGLT2i (group 3) also demonstrated subtle improve-
ment in LV-EF and LV-GLS, but the improvement in 
LV-EF was more prominent in the HF patients with 
SGLT2i treatment (group 4) (p for interaction = 0.003 for 
LV-EF). Multivariable logistic regression analysis showed 
that the use of SGLT2i was significantly associated with 
+5% improvement in LV-EF (adjusted OR, 2.384; 95% 
CI, 1.266–4.448; p = 0.007) (Table  2 and Additional 
file  1: Table  S3). For +10% improvement in LV-EF, the 
use of SGLT2i (adjusted OR, 2.236; 95% CI, 1.106–4.521; 
p = 0.025) and the standard dose of beta-blockers for 
HF (adjusted OR, 2.849; 95% CI, 1.126–7.205; p = 0.027) 
showed significant associations (Table  2 and Additional 





Group 1 No 
HF, no SGLT2i 
(n = 76)
Group 2 No 





Group 3 HF 
(+), no SGLT2i 
(n = 76)
Group 4 HF 










 LAVI (mL/m2) 40.3 (31.0–56.5) 31.8 (28.3–39.9) 34.7 (29.5–44.8) 0.081 48.2 (36.2–68.1) 53.5 (41.6–72.3) 0.860
 PASP (mmHg) 28.0 (24.4–38.6) 26.2 (23.0–29.3) 26.2 (22.6–30.0) 0.808 32.0 (26.2–41.0) 36.4 (28.0–54.0) 0.038
 E velocity (m/s) 0.70 (0.58–0.87) 0.66 (0.59–0.78) 0.63 (0.57–0.78) 0.760 0.73 (0.58–0.87) 0.79 (0.63–1.03) 0.030
 Mitral annular e′ 
velocity (cm/s)
5.7 (4.2–7.2) 6.10 (4.80–7.40) 6.00 (5.00–7.10) 0.403 5.7 (4.2–7.2) 5.10 (3.70–6.50) 0.167
 Mitral annular s’ 
velocity (cm/s)
6.0 (4.7–7.5) 6.7 (5.4–8.4) 6.6 (5.5–7.8) 0.696 5.3 (4.2–6.7) 5.0 (3.8–6.1) 0.377
 Mitral E/e′ ratio 12.6 (9.3–17.1) 10.8 (8.9–14.1) 10.6 (9.0–13.5) 0.742 13.2 (9.8–17.8) 15.6 (11.9–24.3) 0.026
 LV‑GLS (%) 12.5 (9.5–15.5) 15.2 (12.5–16.9) 14.6 (12.1–17.0) 0.962 10.9 (8.4–12.3) 10.3 (7.3–12.5) 0.532
Follow‑up interval 
(months)
13 (8–20) 13 (8–21) 12 (9–19) 0.091 11 (7–16) 14 (8–21) 0.183
Data are expressed as median with interquartile range (Q1–Q3) or as number (percentage)
HF heart failure, SGLT2i sodium-glucose cotransporter 2 inhibitor, NYHA New York Heart Association, DPP-4 dipeptidyl peptidase-4, ACEi angiotensin converting 
enzyme inhibitor, ARB angiotensin receptor blocker, MRA mineralocorticoid antagonist, HbA1c hemoglobin A1c, LV left ventricular, EDV end-diastolic volume, ESV end-
systolic volume, EDD end-diastolic dimension, ESD end-systolic dimension, EF ejection fraction, MI mass index, LAVI left atrial volume index, PASP pulmonary artery 
systolic pressure, GLS global longitudinal strain
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diastolic function parameters (Fig.  2). A reduction in 
mitral E/e’ ratio was observed in the group 2 (from 10.6 
[9.0–13.5] to 10.5 [8.3–14.0]; p = 0.028) and group 4 
(from 15.6 [11.9–24.3] to 13.0 [9.1–19.1]; p < 0.001), but 
not observed in those without SGLT2i treatment (groups 
1 and 3) (Fig.  2e). The group 4 patients also showed a 
significant decrease in PASP (from 36.4 [28.0–54.0] to 
Fig. 2 Changes in LV function and geometry by SGLT2i according to the presence of HF and the use of SGLT2i. Echocardiographic parameters at 
baseline and follow‑up are presented according to the presence of HF and the use of SGLT2i: a LV‑EDD, b LV‑MI, c LV‑EF, d LV‑GLS, e mitral E/e′ ratio, 
and f PASP. Bars represent the median with interquartile range (Q1–Q3). Intra‑group and inter‑group comparisons were performed with paired 
t‑test generalized linear model for repeated measure analysis, respectively. LV left ventricular, EF ejection fraction, GLS global longitudinal strain, EDD 
end‑diastolic dimension, MI mass index, PASP pulmonary arterial systolic pressure; others as in Fig. 1
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32.0 mmHg [26.2–41.0]; p < 0.001), but not in the group 3 
patients (p for interaction < 0.001) (Fig. 2f ).
There was no difference in the changes in echocar-
diographic parameters according to the type of SGLT2i 
(dapagliflozin vs. empagliflozin; Additional file  1: Fig-
ures S1 and S2).
Comparison of LV function changes between HFrEF 
and HFpEF
In patients with HFrEF (LV-EF < 40%), the LV systolic 
function parameters showed significant improvement in 
those with SGLT2i treatment (ΔLV-EF, +8.8% [3.0–17.9]; 
ΔLV-GLS, +1.7% [0.1–3.5]), but not in those without 
SGLT2i treatment (p < 0.001 for both LV-EF and LV-GLS) 
(Fig. 3). Of note, the changes in LV-EF and LV-GLS did 
not show different according to the SGLT2i treatment in 
HFpEF patients.
Similar patterns were observed for LV geometry and 
diastolic function. The HFrEF patients with SGLT2i treat-
ment showed significant decreases in LV-EDD, LV-EDV, 
mitral E/e’ ratio and PASP, whereas the improvements in 
LV geometry and diastolic function were not observed in 
the HFpEF patients with SGLT2i treatment (Fig. 3).
Changes in NT-proBNP levels
We compared the changes in NT-proBNP levels in 
patients with both baseline and follow-up measurement 
(n = 76) (Fig.  4a). The HF patients with SGLT2i treat-
ment (group 4) showed a significant decrease in NT-
proBNP levels (from 1819.6 [547.3–5695.4] to 782.1 pg/
mL [181.5–2954.0]; p = 0.008), but other groups did not 
(p for interaction = 0.028 between group 4 vs. 3).
Among the HF patients with both baseline and follow-
up NT-proBNP measurements (n = 69), the reduction in 
NT-proBNP was observed only in HFrEF patients treated 
with SGLT2i (from 2202.5 [572.4–6131.4] to 767.5 pg/mL 
[183.1–1688.7]; p = 0.001), but not in the HFrEF patients 
without SGLT2i (p for interaction = 0.035 between 
HFrEF with SGLT2i vs. HFrEF without SGLT2i) (Fig. 4b). 
The HFpEF patients did not show significant changes in 
NT-proBNP levels regardless of the use of SGLT2i.
Discussion
In this retrospective cohort study, we observed that the 
use of SGLT2i was associated with improvements in LV 
geometry, systolic and diastolic function in type 2 dia-
betic patients. The improvement in cardiac function by 
SGLT2i was more prominent in HF patients, compared 
to the patients without HF. Of note, among the diabetic 
patients with HF, the improvement in cardiac func-
tion was observed in HFrEF patients, but not in HFpEF 
patients. Our findings provide background for the clini-
cal benefits reported in recent trials, and suggest that the 
benefits of SGLT2i in HF patients may be more promi-
nent in HFrEF, compared to HFpEF.
Established cardiovascular benefits of SGLT2i and potential 
mechanisms
The SGLT2i showed robust evidence for prevention of HF 
and cardiovascular mortality: a meta-analysis of large-
scale trials showed that the use of SGLT2i leads to about 
30% reduction in HF hospitalization and cardiovascular 
mortality in HF patients, and about 20% reduction in 
HF hospitalization and cardiovascular mortality in dia-
betic patients without HF [1–3, 9]. Because these benefits 
Table 2 Multivariate analysis for the improvement in LV-EF
Multivariate logistic regression analysis was performed in the total study population. Univariate factors with p-values < 0.200 entered the multivariate analysis, using 
stepwise backward elimination methods to select the factors for inclusion in the multivariable analysis
LV left ventricular, EF ejection fraction, OR odds ratio, CI confidence interval, HTN hypertension, SGLT2i sodium-glucose cotransporter 2 inhibitor, EDV end-diastolic 
volume, PASP pulmonary artery systolic pressure
a Standard doses of beta-blockers for HF were determined according to the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [6]
+ 5% improvement in LV-EF + 10% improvement in LV-EF
Adjusted OR 95% CI p-value Adjusted OR 95% CI p-value
Age (per +1 year) 0.965 0.937–0.993 0.015 0.975 0.949–1.002 0.070
Male sex – – – 0.271 0.125–0.584 0.001
Hypertension 0.521 0.278–0.975 0.042 – – –
SGLT2i 2.384 1.266–4.488 0.007 2.236 1.106–4.521 0.025
Standard dose of beta‑block‑
ers for  HFa
– – – 2.849 1.126–7.205 0.027
LV‑EDV (per +1 mL) 0.987 0.977–0.996 0.007 – – –
LV‑EF (per +1%) 0.919 0.891–0.948 < 0.001 0.928 0.906–0.950 < 0.001
PASP (per +1 mmHg) 1.025 1.000–1.051 0.049 – – –
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appeared at early phase of the clinical trials, which can-
not be explained by the glucose lowering effect, multiple 
glucose-independent mechanisms have been suggested. 
Most of all, the diuretic effect of SGLT2i would be the 
key component for HF prevention which is different from 
those observed with conventional diuretics: (1) SGLT2i 
Fig. 3 Changes in LV function and geometry by SGLT2i according to the types of HF. The changes in echocardiographic parameters were compared 
between subgroups divided according to the types of HF (HFrEF vs. HFpEF) and the use of SGLT2i: a LV‑EF, b LV‑GLS, c LV‑EDD, d LV‑EDV, e mitral 
E/e′ ratio, and f PASP. Bars represent the median with interquartile range (Q1–Q3). Intra‑group and inter‑group comparisons were performed with 
paired t‑test generalized linear model for repeated measure analysis, respectively. Abbreviations as in Figs. 1 and 2
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do not affect plasma osmolarity (2) activates the tubule-
glomerular feedback through the increased delivery of 
fluid and electrolytes to the macula densa, (3) produces 
a greater fluid clearance from the interstitial space result-
ing in a better congestion relief with minimal impact on 
arterial filling and organ perfusion, and (4) exerts reno-
protective effects [4, 10, 11].
In addition, the SGLT2i may provide cardiovascular 
benefits by an improved myocardial energy metabolism 
[4, 12]. The use of SGLT2i results in hyperketonemia, 
and switches myocardial fuel utilization from glucose 
to ketone bodies and free fatty acid, resulting in a more 
efficient ATP production [13, 14]. Also, the SGLT2i can 
inhibit cardiac  Na+-H+ exchanger (NHE), resulting in 
the reduction of intracellular calcium and an increase 
of mitochondrial  Ca2+, which restores mitochondrial 
function and redox state, activates ATP production [15]. 
These potential mechanistic background was further 
supported by animal model studies: the use of SGLT2i 
attenuated myocardial oxidative stress and fibrosis in dia-
betic mice heart, and improved coronary microvascular 
function and cardiac contractility in pre-diabetic mice 
model [16, 17].
Despite the absence of overt structural heart disease or 
symptoms of HF, the diabetic patients are considered as 
“stage A HF” because these patients are at high risk for 
HF [5, 18]. These patients often demonstrate subclinical 
myocardial dysfunction, which can be detected by dias-
tolic dysfunction and LV hypertrophy [18, 19]. Further-
more, recent studies showed that impaired LV-GLS is 
a sensitive marker in diabetic patients with stage A HF 
[20, 21]. In our study, patients without overt HF can be 
considered as having stages A or B HF due to the pres-
ence of diabetes and the impaired LV-GLS values at base-
line (LV-GLS 15.2% in group 1 and 14.6% in group 2), 
despite the preserved LV-EF. Given the high risk of HF 
development as well as the presence of subclinical LV 
dysfunction, there is a need for effective prevention of LV 
function deterioration in these patients. Several studies 
that showed improvements in LV diastolic function and 
reduction in LV-MI by SGLT2i in diabetic patients with-
out overt HF [22, 23]. Also, a reduction in LV-MI in dia-
betic patients with coronary artery disease was observed 
in the Effects of Empagliflozin on Cardiac Structure in 
Patients with Type 2 Diabetes (EMPAHEART) Cardi-
oLink-6 trial [24]. Our findings are consistent with these 
studies that the use of SGLT2i resulted in small but sig-
nificant improvements in LV geometry and diastolic 
function in diabetic patients without overt HF. Adding 
to this, we observed significant improvements in LV-EF 
and LV-GLS in diabetic patients without overt HF. These 
structural changes support the mechanistic background 
of SGLT2i in terms of the improved myocardial intrinsic 
function and energetics, and also explain the clinical ben-
efits of SGLT2i for prevention of HF in diabetic patients 
even at the early stage without structural heart disease or 
HF symptoms.
Cardioprotective effects of SGLT2i in patients with HF
The glucose-independent benefits of SGLT2i have been 
confirmed by recently published clinical trials: according 
to the DAPA-HF trial, the use of dapagliflozin reduced 
the composite of worsening HF or cardiovascular death 
to 27% in HFrEF patients, and the results were not differ-
ent between those with diabetes and those without [25]. 
Also, the Dapagliflozin Effects on Biomarkers, Symptoms 
and Functional Status in Patients with HF with Reduced 
Ejection Fraction (DEFINE-HF) trial reported clinically 
meaningful improvements in HF-related health status 
or natriuretic peptides in HF patients regardless of the 
Fig. 4 Changes in NT‑proBNP levels by SGLT2i according to the presence and types of HF. The changes in the levels of NT‑proBNP were compared 
according to the use of SGLT2i and the presence of HF (a), and the types of HF (b). Abbreviations: as in Figs. 1 and 2
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presence of diabetes [26]. Therefore, it can be reason-
able to assume that the cardiovascular benefits of SGLT2i 
would be independent to its glucose-lowering effect, as 
demonstrated in various non-diabetic animal models. 
Byrne et  al. investigated non-diabetic mice subjected to 
pressure overload and found that the 2-week of empagli-
flozin treatment preserved LV systolic function, which 
was sustained ex vivo in the absence of ketones or hemo-
dynamic changes [27]. In a rat model of hypertensive HF, 
empagliflozin improved LV systolic function, reduced LV 
cavity size, and attenuated cardiac fibrosis [28]. Recently, 
Zhang et al. administered dapagliflozin to a pig model of 
HFpEF and observed that dapagliflozin reduced blood 
pressure, mitigated LV concentric remodeling, and atten-
uated hypertension-induced macrovascular inflamma-
tory response [29].
In the present study, we observed more prominent 
improvements in LV function by SGLT2i in diabetic 
patients with HF compared to those without, which was 
independent of the use of cardioprotective medications 
for HF (ACEi, ARB, beta-blockers, and MRA). Many 
patients with HF (groups 3 and 4) had uptitration of HF 
medications during follow-up, and reached the standard 
dose for optimal HF management. Indeed, we observed 
that the use of standard dose of beta-blockers for HF was 
associated with an improved LV-EF among the diabetic 
patients with HF. More importantly, the use of cardiopro-
tective medications and their changes were not different 
between those treated with SGLT2i and those without 
(groups 3 vs. 4), and the improvement of LV function by 
SGLT2i use was observed even after adjusting for the use 
of cardioprotective medications and their changes.
Differences in SGLT2i effects between HFrEF vs. HFpEF
Several studies showed the changes in LV function 
parameters in diabetic patients according to the types of 
HF. A retrospective echocardiographic study of diabetic 
patients on either SGLT2i or DPP-4 inhibitors reported 
reductions in E/e’ ratio and NT-proBNP levels by SGLT2i 
in patients with LV-EF < 40%, but not in those with 
LV-EF ≥ 40% [30]. However, beneficial effect of SGLT2i 
has also been suggested in patients with HFpEF: in an 
echocardiographic study by Soga et  al. the mitral E/e’ 
ratio, LV-MI, and LAVI were decreased with dapagliflo-
zin treatment among diabetic patients with high preva-
lence of HFpEF (69%) and HFmrEF (17%), whereas the 
improvement in LV systolic function and the reduction in 
BNP levels were minimal [31]. A recent prospective study 
of diabetic patients with HFpEF demonstrated reductions 
in E/e’ ratio and BNP level, along with improved renal 
function, decreased fat volumes and reduced oxidative 
stress [32].
In the present study, we advanced to the comparison 
of echocardiographic changes by SGLT2i in diabetic 
patients according to the presence and types of HF. The 
improvements in LV function and geometry were more 
prominent in HF patients than in those with HF, and 
these improvements were mainly derived in the HFrEF 
patients rather than those with HFpEF. Of note, the 
reduction in NT-proBNP levels was observed only in 
those with HFrEF patients, in whom the baseline NT-
proBNP levels were significantly higher compared to the 
HFpEF patients. These findings are in line with the study 
by Soga et al. where the levels of BNP were decrease by 
SGLT2i among those with baseline BNP levels ≥ 100 pg/
mL [31]. These findings suggest that the improvement in 
cardiac function by SGLT2i would be attributable to the 
effective volume reduction and possibly to the alleviation 
of activated neurohormonal axis.
Based on these findings, we suppose that the action 
mechanisms of SGLT2i can provide possible explanation 
on the different echocardiographic responses between 
HFrEF and HFpEF. The levels of natriuretic peptide 
are higher in HFrEF than in HFpEF, due to the further 
stretched LV by volume overload and accompanied neu-
rohormonal activation [33, 34]. Several network analysis 
studies of multiple biomarkers showed that the elevated 
NT-proBNP is one of the hub of HFrEF pathophysiology 
[33, 35], together with the activated biological pathways 
for cellular proliferation and cardiac hypertrophy [35]. 
In contrast, the biomarker studies showed that the main 
pathophysiology of HFpEF is the inflammation, integrin 
signaling, and extracellular matrix organization, rather 
than myocardial stretching characterized by elevated 
NT-proBNP levels. Therefore, it can be postulated that 
the use of SGLT2i may exert effective volume reduction 
effects, which would be more beneficial in HFrEF, but the 
benefits would be blunted in HFpEF.
However, our study does not necessarily indicate the 
lack of benefits by SGLT2i in HFpEF, and our findings 
should be interpreted with caution. Our results would 
be enough to explain the benefit of SGLT2i in HFrEF in 
terms of HF prevention, but not sufficient to insist the 
lack of SGLT2i-induced benefits in HFpEF. At least, given 
the underlying pathophysiology of HFrEF and HFpEF, we 
suppose that the benefits of SGLT2i in HFpEF patients 
would be smaller than those in HFrEF patients. Ongoing 
clinical trials will provide more concrete evidence for the 
effects of SGLT2i in HFpEF.
Limitations
Our study has several limitations. First, our study was a 
single-center retrospective analysis without pre-specified 
schedules for echocardiography. Instead, we performed 
propensity score matching which was successful in terms 
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of comorbidities, medications, and follow-up intervals. 
Also, the statistical power was acceptable for addressing 
the changes in echocardiographic parameters in the given 
sample size. Nonetheless, interpretation of our results 
needs caution due to the innate limitations of a retro-
spective study. Second, the diagnosis of HF was based 
on the information available through medical records, 
which reflected usual practice. However, the definition of 
HF in the study was not different from the clinical guide-
lines [5, 6]. Third, we did not observe comparative ben-
efits of SGLT2i on renal outcomes or glycemic control, 
which were reported in recent trials [36, 37]. We assume 
that the lack of renal benefits in our study would be due 
to the small number of study population and the lack of 
prespecified schedules for measurements. Finally, we did 
not investigate the in-depth mechanisms of SGLT2i, and 
therefore, the mechanistic interpretations of our findings 
are mainly speculations. While the improvements in LV 
function by SGLT2i in our study support the cardiovas-
cular benefits of SGLT2i, future studies are required to 
clarify the biological basis for the effects of SGLT2i on 
HF.
Conclusion
In this retrospective cohort study, the use of SGLT2i 
improved LV systolic and diastolic function, as well as 
LV geometry, in diabetic patients regardless of the pres-
ence of HF. The improvement in LV function was more 
prominent in those with HFrEF patients compared to 
those with HFpEF or those without HF. These effects of 
SGLT2i may contribute to the reduction in HF morbidity 
and mortality in diabetic patients.
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